While Kymera Therapeutics Inc has overperformed by 0.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KYMR rose by 64.16%, with highs and lows ranging from $68.80 to $19.44, whereas the simple moving average jumped by 53.90% in the last 200 days.
On November 03, 2025, Guggenheim started tracking Kymera Therapeutics Inc (NASDAQ: KYMR) recommending Buy. A report published by B. Riley Securities on October 24, 2025, Reiterated its previous ‘Buy’ rating for KYMR. Mizuho also rated KYMR shares as ‘Outperform’, setting a target price of $81 on the company’s shares in an initiating report dated October 21, 2025. H.C. Wainwright Reiterated the rating as Buy on September 18, 2025, but set its price target from $60 to $70. Barclays initiated its ‘Overweight’ rating for KYMR, as published in its report on September 17, 2025. RBC Capital Mkts’s report from September 16, 2025 suggests a price prediction of $70 for KYMR shares, giving the stock a ‘Outperform’ rating. B. Riley Securities also rated the stock as ‘Buy’.
Analysis of Kymera Therapeutics Inc (KYMR)
Further, the quarter-over-quarter decrease in sales is -26.12%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Kymera Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -32.09% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.38, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 757.17K can be a very valuable indicator of volatility for KYMR stock. On a monthly basis, the volatility of the stock is set at 5.85%, whereas on a weekly basis, it is put at 5.60%, with a gain of 2.69% over the past seven days. Furthermore, long-term investors anticipate a median target price of $76.68, showing growth from the present price of $66.04, which can serve as yet another indication of whether KYMR is worth investing in or should be passed over.
How Do You Analyze Kymera Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.20%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 97.75% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
